



The Washington Post

The Health 202: Trump's latest move to lower drug spending pits patients versus insurers



POLITICO

POLITICO Pulse

Examining the latest in health care policy every weekday morning

PATIENT GROUPS: NEW STUDY SHOWS INSURERS HAVE ENOUGH TOOLS TO MANAGE COSTS OF DRUGS IN 'PROTECTED CLASSES'

PATIENT ENGAGEMENT HIT
xtelligent HEALTHCARE MEDIA

Part D Drug Price Proposal Could Limit Patient Access to Care

THE

NATIONAL LAW REVIEW

Implications

On November 29, 2018, the Partnership for Part D Access (the Partnership) released a study, which casts doubt on the beneficial effects of the new proposal.



Advocacy groups push back against CMS protected drugs claims



An Inside Washington news service

HHS May Stop Step Therapy In One Instance, While Pushing It In Another

FierceHealthcare

Patient groups decry Medicare Part D proposal, saying it will restrict critical access

MEDPAGE TODAY®

Medicare Part D Proposal Draws Criticism

Bloomberg Law

Leave Medicare Drug Coverage Alone, Patient Advocates Say

The New York Times
Trump Pledged to End H.I.V. But His Policies Veer the Other Way.



TELL CMS: PRESERVE MEDICARE'S SIX PROTECTED CLASSES

Modern Healthcare

The leader in healthcare business news, research & data

Azar: HHS examining insurer policy requiring patients to start over on step therapy

Washington Examiner

Outside groups prepare to fight Trump drug pricing proposal



Trump's Part D proposal puts some seniors at risk

BY FORMER GOV. HOWARD DEAN (D-VT), OPINION CONTRIBUTOR — 02/04/19 08:30 AM EST
THE VIEWS EXPRESSED BY CONTRIBUTORS ARE THEIR OWN AND NOT THE VIEW OF THE HILL